Healthcare Equipment and Supplies
Company Overview of TearScience, Inc.
TearScience, Inc. develops diagnostic and treatment devices for dry eye cases. It offers LipiView ocular surface interferometers for observing the tear film, capturing images of the tear film, processing pixels, and evaluating them; and Meibomian gland evaluators for evaluating meibomian gland secretions through gland expression for determining if glands are blocked. The company also provides LipiFlow thermal pulsation devices that treat evaporative dry eye patients; and apply heat to the back of the eyelid, and an intermittent gentle pressure to the outer surface to release the obstruction from meibomian glands and allow the natural flow of lipids to resume. TearScience, Inc. markets its pr...
5151 McCrimmon Parkway
Morrisville, NC 27560
Founded in 2005
Key Executives for TearScience, Inc.
Co-Founder and Chief Technical Officer
Senior Vice President of European Region
Chief Commercial Officer and Senior Vice President
Compensation as of Fiscal Year 2013.
TearScience, Inc. Key Developments
TearScience, Inc. Presents at Piper Jaffray 24th Annual Health Care Conference, Nov-28-2012 11:50 AM
Nov 24 12
TearScience, Inc. Presents at Piper Jaffray 24th Annual Health Care Conference, Nov-28-2012 11:50 AM. Venue: The New York Palace, 455 Madison Avenue, New York, NY 10022, United States.
TearScience, Inc. Names Wade Hampton as Senior Vice President and Chief Commercial Officer
Oct 19 12
TearScience, Inc. has appointed Wade Hampton as senior vice president and chief commercial officer. Hampton will focus on the commercialization of TearScience's dry eye treatment system, particularly in North America. Previously, Hampton was a managing partner of Baron Minor Group, an aesthetic, surgical and ophthalmic medical device company. His resume also includes stints at Accuray Inc. and Lumenis Inc.
Tearscience, Inc.'s Lipiflow Multi-Center Clinical Study Shows Improved Meibomian Gland Secretions and Dry Eye Symptoms
Mar 5 12
The results of a randomized, controlled clinical study of a new treatment for Meibomian Gland Dysfunction (MGD) and evaporative dry eye disease, using the LipiFlow(R) Thermal Pulsation System, was reported in Cornea to provide sustained improvement, on average, in both signs and symptoms. Further, this study demonstrated the clinical utility, safety and effectiveness of LipiFlow(R) in adult patients with MGD and dry eye symptoms. The clinical study was supported by TearScience, Inc. and involved nine U.S.-based investigational centers and 139 patients (278 eyes). It compared results for patients treated with a single LipiFlow(R) treatment to a warm compress control for the treatment of MGD. The average total Meibomian gland score for patients who received a single LipiFlow(R) treatment more than doubled from 6.3 +/- 3.5 at the baseline to 16.7 +/- 8.7 at 4 weeks. The increase in the average total Meibomian score reflected an improvement in both the quality and quantity of Meibomian glands secreting lipids, which keep the water portion of tears from evaporating too quickly, as compared to before the LipiFlow(R) treatment. Two different recognized symptom questionnaires were used in the study: the Standard Patient Evaluation of Eye Dryness (SPEED) and the Ocular Surface Disease Index (OSDI). The average total SPEED score for patients who received a single LipiFlow(R) treatment decreased from 14.3 +/- 4.8 at the baseline to 7.6 +/- 5.8 at 4 weeks, demonstrating a mean reduction in dry eye symptoms. Similarly, the average OSDI score decreased from 32.0 +/- 20.0 at baseline to 16.6 +/- 18.1 at 4 weeks. In the study, there were no serious device-related adverse events reported for the LipiFlow(R) System. Non-serious device-related adverse events included moderate eyelid pain during treatment (3eyes) and transient, moderate eye redness after treatment (1 eye). LipiFlow(R), which applies heat and gentle pressure to a patient's eyelid, is designed to liquefy and evacuate obstructions in Meibomian glands during a 12-minute in-office procedure. The goal of unblocking the glands is to allow them to resume their natural production of lipids required for a healthy tear film. TearScience(R) manufactures and sells a complete system for eye care physicians, which is comprised of the LipiFlow(R) and the LipiView(R) Ocular Surface Interferometer, which allows physicians to assess a patient's tear film.
Similar Private Companies By Industry
Recent Private Companies Transactions
February 25, 2013